Mga Batayang Estadistika
| CIK | 1205922 |
SEC Filings
All companies that sell securities in the United States must register with the Securities and Exchange Commission (SEC) and file reports on a regular basis.
These reports include company annual reports (10K, 10Q), news updates (8K), investor presentations (found in 8Ks), insider trades (form 4), ownership reports (13D, and 13G), and reports related to the specific securities sold, such as registration statements and prospectus. This page shows recent SEC filings related to Vaccinex, Inc.
SEC Filings (Chronological Order)
Halaman ini menyediakan daftar lengkap dan kronologis dari Pengajuan SEC, tidak termasuk pengajuan kepemilikan yang kami sediakan di tempat lain.
| April 15, 2025 |
Policy for the Recovery of Erroneously Awarded Compensation Exhibit 97Vaccinex, Inc. Policy for the Recovery of Erroneously Awarded Compensation This Policy for the Recovery of Erroneously Awarded Compensation Policy (this “Policy”) has been adopted by the Board of Directors (the “Board”) of Vaccinex, Inc. (the “Company”), in accordance with the requirements of the Recovery Rules to implement a written policy for the recovery of erroneously awarded compens |
|
| April 15, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38624 Vaccinex, Inc. |
|
| April 15, 2025 |
Exhibit 19.1 VACCINEX, INC. TRADING COMPLIANCE POLICY This Trading Compliance Policy (this "Policy") describes the standards of Vaccinex, Inc. (the "Company") on trading, and causing the trading of, the Company’s securities or securities of certain other publicly-traded companies while in possession of confidential information. This policy prohibits trading in certain circumstances and applies to |
|
| April 1, 2025 |
SEC File Number: 001-38624 CUSIP Number: 918640301 UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D. |
|
| March 27, 2025 |
15-12G UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 15 CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934 OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-38624 Vaccinex, Inc. (Exact name of registrant as specified in it |
|
| March 25, 2025 |
As filed with the Securities and Exchange Commission on March 25, 2025 As filed with the Securities and Exchange Commission on March 25, 2025 Registration No. |
|
| March 25, 2025 |
As filed with the Securities and Exchange Commission on March 25, 2025 As filed with the Securities and Exchange Commission on March 25, 2025 Registration No. |
|
| March 25, 2025 |
As filed with the Securities and Exchange Commission on March 25, 2025 As filed with the Securities and Exchange Commission on March 25, 2025 Registration No. |
|
| March 25, 2025 |
As filed with the Securities and Exchange Commission on March 25, 2025 As filed with the Securities and Exchange Commission on March 25, 2025 Registration No. |
|
| March 25, 2025 |
As filed with the Securities and Exchange Commission on March 25, 2025 As filed with the Securities and Exchange Commission on March 25, 2025 Registration No. |
|
| March 25, 2025 |
As filed with the Securities and Exchange Commission on March 25, 2025 As filed with the Securities and Exchange Commission on March 25, 2025 Registration No. |
|
| March 25, 2025 |
As filed with the Securities and Exchange Commission on March 25, 2025 POS AM As filed with the Securities and Exchange Commission on March 25, 2025 Registration No. |
|
| March 25, 2025 |
As filed with the Securities and Exchange Commission on March 25, 2025 As filed with the Securities and Exchange Commission on March 25, 2025 Registration No. |
|
| March 25, 2025 |
As filed with the Securities and Exchange Commission on March 25, 2025 As filed with the Securities and Exchange Commission on March 25, 2025 Registration No. |
|
| March 25, 2025 |
As filed with the Securities and Exchange Commission on March 25, 2025 POS AM As filed with the Securities and Exchange Commission on March 25, 2025 Registration No. |
|
| March 25, 2025 |
As filed with the Securities and Exchange Commission on March 25, 2025 As filed with the Securities and Exchange Commission on March 25, 2025 Registration No. |
|
| March 25, 2025 |
As filed with the Securities and Exchange Commission on March 25, 2025 As filed with the Securities and Exchange Commission on March 25, 2025 Registration No. |
|
| March 25, 2025 |
As filed with the Securities and Exchange Commission on March 25, 2025 POS AM As filed with the Securities and Exchange Commission on March 25, 2025 Registration No. |
|
| March 25, 2025 |
As filed with the Securities and Exchange Commission on March 25, 2025 POS AM As filed with the Securities and Exchange Commission on March 25, 2025 Registration No. |
|
| March 25, 2025 |
As filed with the Securities and Exchange Commission on March 25, 2025 POS AM As filed with the Securities and Exchange Commission on March 25, 2025 Registration No. |
|
| March 25, 2025 |
As filed with the Securities and Exchange Commission on March 25, 2025 POS AM As filed with the Securities and Exchange Commission on March 25, 2025 Registration No. |
|
| March 25, 2025 |
As filed with the Securities and Exchange Commission on March 25, 2025 S-8 POS As filed with the Securities and Exchange Commission on March 25, 2025 Registration No. |
|
| March 19, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 18, 2025 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 17, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. C. 20549 FORM 25 NOTIFICATION OF REMOVAL FROM LISTING AND/OR REGISTRATION UNDER SECTION 12(b) OF THE SECURITIES EXCHANGE ACT OF 1934. Commission File Number 001-38624 Vaccinex, Inc. The Nasdaq Stock Market LLC (Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered) 1895 Mount |
|
| March 7, 2025 |
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market EX-99.1 Exhibit 99.1 Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market ROCHESTER, N.Y., Mar. 7, 2025 (GLOBE NEWSWIRE) – Vaccinex, Inc. (OTC: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today |
|
| March 7, 2025 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 7, 2025 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| December 17, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): December 16, 2024 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File N |
|
| December 17, 2024 |
Vaccinex Announces Receipt of Delisting Notification from Nasdaq Exhibit 99.1 Vaccinex Announces Receipt of Delisting Notification from Nasdaq ROCHESTER, N.Y., December 17, 2024 (GLOBE NEWSWIRE) — Vaccinex, Inc. (Nasdaq: VCNX) (“Vaccinex” or the “Company”), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease by blocking astrogliosis and neuroinflammation through the inhibition of SEMA4D, today announ |
|
| November 18, 2024 |
VCNX / Vaccinex, Inc. / Zauderer Maurice - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 6) Under the Securities Exchange Act of 1934 VACCINEX, INC. (Name of Issuer) Common Stock, Par Value $0.0001 per share (Title of Class of Securities) 918640 301 (CUSIP Number) Maurice Zauderer c/o Vaccinex, Inc. 1895 Mount Hope Ave Rochester, New York 14620 Telephone: (585) 271-2700 (Name, |
|
| November 14, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of November 13, 2024, between Vaccinex, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set f |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 13, 2024 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38624 Vaccinex, Inc. ( |
|
| November 14, 2024 |
Pre-Funded Common Stock Purchase Warrant issued to FCMI Parent Co., dated November 14, 2024 Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, NEITHER MAY BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| November 14, 2024 |
VCNX / Vaccinex, Inc. / ARMISTICE CAPITAL, LLC Passive Investment SC 13G 1 armistice-vcnx093024.htm UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, DC 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* VACCINEX, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 918640301 (CUSIP Number) September 30, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropri |
|
| October 25, 2024 |
1,601,238 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-282679 PROSPECTUS 1,601,238 Shares of Common Stock This prospectus relates to the resale, from time to time, by the selling stockholders identified in this prospectus under the caption “Selling Stockholders,” or the Selling Stockholders, of up to 1,601,238 shares of our common stock, par value $0.0001 per share, or the Shares, |
|
| October 22, 2024 |
Vaccinex, Inc. 1895 Mount Hope Avenue Rochester, New York 14620 Vaccinex, Inc. 1895 Mount Hope Avenue Rochester, New York 14620 October 22, 2024 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Vaccinex, Inc. Registration Statement on Form S-3 Filed October 16, 2024 File No. 333-282679 Request for Acceleration of Effectiveness Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Sec |
|
| October 16, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Vaccinex, Inc. |
|
| October 16, 2024 |
As filed with the Securities and Exchange Commission on October 16, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on October 16, 2024 Registration Statement No. |
|
| October 16, 2024 |
EX-24.1 Exhibit 24.1 VACCINEX, INC. POWER OF ATTORNEY Each of the undersigned directors and officers of Vaccinex, Inc., a Delaware corporation (the “Registrant”), hereby constitutes and appoints Maurice Zauderer, Ph.D., and Jill Sanchez, and each of them, with full power of substitution and resubstitution and full power to act without the other, his or her true and lawful attorney-in-fact and agen |
|
| October 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 7, 2024 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Num |
|
| September 20, 2024 |
VCNX / Vaccinex, Inc. / Zauderer Maurice - SC 13D/A Activist Investment SC 13D/A 1 d868772dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 5) Under the Securities Exchange Act of 1934 VACCINEX, INC. (Name of Issuer) Common Stock, Par Value $0.0001 per share (Title of Class of Securities) 918640 301 (CUSIP Number) Maurice Zauderer c/o Vaccinex, Inc. 1895 Mount Hope Ave Rochester, New York 14620 Tel |
|
| September 20, 2024 |
VCNX / Vaccinex, Inc. / Fcmi Parent Co. - SC 13D/A Activist Investment SC 13D/A 1 d825039dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 12) Under the Securities Exchange Act of 1934 VACCINEX, INC. (Name of Issuer) Common Stock, Par Value $0.0001 per share (Title of Class of Securities) 918640 303 (CUSIP Number) Dan Scheiner FCMI Parent Co. 181 Bay Street, Suite 250 Toronto, Ontario Canada M5J 2 |
|
| September 19, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, NEITHER MAY BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| September 19, 2024 |
EX-10.1 Exhibit 10.1 VACCINEX, INC. 1895 Mount Hope Avenue Rochester, New York 14620 September 17, 2024 Holder of Common Stock Purchase Warrants Re: Inducement Offer to Exercise Common Stock Purchase Warrants Dear Holder: Vaccinex, Inc. (the “Company”) is pleased to offer to you (“Holder”, “you” or similar terminology) (i) the opportunity to receive new warrants to purchase shares of the Company’s |
|
| September 19, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 17, 2024 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File |
|
| September 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 10, 2024 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File |
|
| August 20, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 20, 2024 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 14, 2024 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 14, 2024 |
Exhibit 99.1 Vaccinex Provides Update on New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab in Alzheimer’s Disease and Plans to Pursue a Development Partnership Company reviews goals and significance of the study and outlines development strategy in Mild Cognitive Impairment due to Alzheimer’s disease ROCHESTER, N.Y., August 14, 2024 – Vaccinex (Nasdaq: VCNX) today provided an update on new |
|
| August 14, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38624 Vaccinex, Inc. (Exact |
|
| August 7, 2024 |
VCNX / Vaccinex, Inc. / Fcmi Parent Co. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 11) Under the Securities Exchange Act of 1934 VACCINEX, INC. (Name of Issuer) Common Stock, Par Value $0.0001 per share (Title of Class of Securities) 918640 202 (CUSIP Number) Thomas J. Rice Baker & McKenzie LLP 452 Fifth Avenue New York NY 10018 (212) 626-4100 (Name, Address and Telephone |
|
| August 1, 2024 |
VCNX / Vaccinex, Inc. / Fcmi Parent Co. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 10) Under the Securities Exchange Act of 1934 VACCINEX, INC. (Name of Issuer) Common Stock, Par Value $0.0001 per share (Title of Class of Securities) 918640 202 (CUSIP Number) Thomas J. Rice Baker & McKenzie LLP 452 Fifth Avenue New York NY 10018 (212) 626-4100 (Name, Address and Telephone |
|
| July 31, 2024 |
Exhibit 99.1 Vaccinex Reports Positive Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab in Alzheimer’s Disease Results affirm expectation of a novel mechanism of action targeting astrocyte activation to delay progression of Alzheimer’s disease from early stage Mild Cognitive Impairment Findings echo previous phase 2 results in Huntington’s disease based on similarities to neuroimmune pathology in |
|
| July 31, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 31, 2024 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| July 8, 2024 |
490,509 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-280535 PROSPECTUS 490,509 Shares of Common Stock This prospectus relates to the resale, from time to time, by the selling stockholders identified in this prospectus under the caption “Selling Stockholders,” or the Selling Stockholders, of up to 490,509 shares of our common stock, par value $0.0001 per share, or the Shares, com |
|
| July 2, 2024 |
Vaccinex, Inc. 1895 Mount Hope Avenue Rochester, New York 14620 Vaccinex, Inc. 1895 Mount Hope Avenue Rochester, New York 14620 July 2, 2024 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Vaccinex, Inc. Registration Statement on Form S-3 Filed June 27, 2024 File No. 333-280535 Request for Acceleration of Effectiveness Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Se |
|
| June 27, 2024 |
As filed with the Securities and Exchange Commission on June 27, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on June 27, 2024 Registration Statement No. |
|
| June 27, 2024 |
Exhibit 24.1 VACCINEX, INC. POWER OF ATTORNEY Each of the undersigned directors and officers of Vaccinex, Inc., a Delaware corporation (the “Registrant”), hereby constitutes and appoints Maurice Zauderer, Ph.D., and Jill Sanchez, and each of them, with full power of substitution and resubstitution and full power to act without the other, his or her true and lawful attorney-in-fact and agent to act |
|
| June 27, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Vaccinex, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, |
|
| June 6, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 6, 2024 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Number |
|
| June 6, 2024 |
Exhibit 99.1 Vaccinex Reports Completion of Last Patient Visit in Randomized, SIGNAL-AD Phase 1b/2 Study of Pepinemab Treatment for Alzheimer’s Disease Company expects to lock database in June and remains on track to report key outcomes later in July. Pepinemab targets astrocyte reactivity and neuroinflammation, believed to be key drivers of neurodegeneration. ROCHESTER, N.Y., June 6, 2024 — Vacci |
|
| May 15, 2024 |
Exhibit 4.4 AMENDMENT AND RESTATEMENT OF THE VACCINEX, INC. COMMON STOCK PURCHASE WARRANT This Amendment and Restatement (this “Amendment”), dated as of [•], 2024 (the “Effective Date”), is made and entered into by and between Vaccinex, Inc., a Delaware corporation (the “Company”), and [•] (the “Holder”) and amends the Common Stock Purchase Warrant to purchase up to [•] shares of the Company’s com |
|
| May 15, 2024 |
Warrant Shares: Initial Exercise Date: [ ], 2024 Issue Date: [ ], 2024 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, NEITHER MAY BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| May 15, 2024 |
Exhibit 4.3 AMENDMENT AND RESTATEMENT OF THE VACCINEX, INC. COMMON STOCK PURCHASE WARRANT This Amendment and Restatement (this “Amendment”), dated as of [•], 2024 (the “Effective Date”), is made and entered into by and between Vaccinex, Inc., a Delaware corporation (the “Company”), and [•] (the “Holder”) and amends the Common Stock Purchase Warrant to purchase up to [•] shares of the Company’s com |
|
| May 15, 2024 |
Warrant Shares: Initial Exercise Date: [ ], 2023 Issue Date: [ ], 2023 FORM OF COMMON STOCK PURCHASE WARRANT VACCINEX, INC. |
|
| May 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2024 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38624 Vaccinex, Inc. (Exac |
|
| May 15, 2024 |
Exhibit 4.5 AMENDMENT AND RESTATEMENT OF THE VACCINEX, INC. COMMON STOCK PURCHASE WARRANT This Amendment and Restatement (this “Amendment”), dated as of [•], 2024 (the “Effective Date”), is made and entered into by and between Vaccinex, Inc., a Delaware corporation (the “Company”), and [•] (the “Holder”) and amends the Common Stock Purchase Warrant to purchase up to [•] shares of the Company’s com |
|
| May 15, 2024 |
Warrant Shares: Initial Exercise Date: [ ], 2023 Issue Date: [ ], 2023 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, MAY NOT BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REGISTRATION STATEMENT UNDER THE SECURITIES ACT OR PURSUANT TO AN AVAILABLE EXEMPTION FROM, OR IN A TRANSACTION NOT SUBJECT TO, THE REGISTRATION REQUIREMENTS OF THE SECURITIES ACT AND IN ACCORDANCE WITH APPLICABLE STATE SECURITIES LAWS. |
|
| May 10, 2024 |
EX-FILING FEES Exhibit 107 CALCULATION OF FILING FEE TABLE Form S-8 (Form Type) Vaccinex, Inc. |
|
| May 10, 2024 |
As filed with the U.S. Securities and Exchange Commission on May 10, 2024 S-8 As filed with the U.S. Securities and Exchange Commission on May 10, 2024 Registration No. 333- SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-8 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 16-1603202 (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Iden |
|
| May 9, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 9, 2024 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Number) |
|
| May 9, 2024 |
Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-278968 PROSPECTUS Up to 193,000 Shares of Common Stock Up to 193,000 Warrants to Purchase up to 193,000 Shares of Common Stock This prospectus relates to the resale, from time to time, by the selling securityholders identified in this prospectus under the caption “Selling Securityholders,” or the Selling Securityholders, of (i |
|
| May 8, 2024 |
As filed with the Securities and Exchange Commission on May 8, 2024 Table of Contents As filed with the Securities and Exchange Commission on May 8, 2024 Registration Statement No. |
|
| May 2, 2024 |
Vaccinex, Inc. 1895 Mount Hope Avenue Rochester, New York 14620 Vaccinex, Inc. 1895 Mount Hope Avenue Rochester, New York 14620 May 2, 2024 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Vaccinex, Inc. Registration Statement on Form S-3 Filed April 26, 2024 File No. 333-278968 Request for Acceleration of Effectiveness Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Se |
|
| April 26, 2024 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Vaccinex, Inc. |
|
| April 26, 2024 |
EX-24.1 Exhibit 24.1 VACCINEX, INC. POWER OF ATTORNEY Each of the undersigned directors and officers of Vaccinex, Inc., a Delaware corporation (the “Registrant”), hereby constitutes and appoints Maurice Zauderer, Ph.D., and Jill Sanchez, and each of them, with full power of substitution and resubstitution and full power to act without the other, his or her true and lawful attorney-in-fact and agen |
|
| April 26, 2024 |
As filed with the Securities and Exchange Commission on April 26, 2024 Table of Contents As filed with the Securities and Exchange Commission on April 26, 2024 Registration Statement No. |
|
| April 25, 2024 |
Policy for the Recovery of Erroneously Awarded Compensation Exhibit 97 Vaccinex, Inc. Policy for the Recovery of Erroneously Awarded Compensation This Policy for the Recovery of Erroneously Awarded Compensation Policy (this “Policy”) has been adopted by the Board of Directors (the “Board”) of Vaccinex, Inc. (the “Company”), in accordance with the requirements of the Recovery Rules to implement a written policy for the recovery of erroneously awarded compen |
|
| April 25, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A Amendment Number 1 (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001- |
|
| April 16, 2024 |
433,525 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-278467 PROSPECTUS 433,525 Shares of Common Stock This prospectus relates to the resale, from time to time, by the selling stockholders identified in this prospectus under the caption “Selling Stockholders,” or the Selling Stockholders, of up to 433,525 shares of our common stock, par value $0.0001 per share, or the Shares, com |
|
| April 12, 2024 |
Vaccinex, Inc. 1895 Mount Hope Avenue Rochester, New York 14620 Vaccinex, Inc. 1895 Mount Hope Avenue Rochester, New York 14620 April 12, 2024 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Vaccinex, Inc. Registration Statement on Form S-3 Filed April 2, 2024 File No. 333-278467 Request for Acceleration of Effectiveness Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securiti |
|
| April 12, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): April 11, 2024 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| April 2, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-38624 Vaccinex, Inc. |
|
| April 2, 2024 |
Policy for the Recovery of Erroneously Awarded Compensation Exhibit 97Vaccinex, Inc. Policy for the Recovery of Erroneously Awarded Compensation This Policy for the Recovery of Erroneously Awarded Compensation Policy (this “Policy”) has been adopted by the Board of Directors (the “Board”) of Vaccinex, Inc. (the “Company”), in accordance with the requirements of the Recovery Rules to implement a written policy for the recovery of erroneously awarded compens |
|
| April 2, 2024 |
As filed with the Securities and Exchange Commission on April 2, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on April 2, 2024 Registration Statement No. |
|
| April 2, 2024 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 2, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Vaccinex, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stoc |
|
| April 2, 2024 |
NT 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 12b-25 NOTIFICATION OF LATE FILING (Check One) ☒ Form 10-K ☐ Form 20-F ☐ Form 11-K ☐ Form 10-Q ☐ Form 10-D ☐ Form N-CEN ☐ Form N-CSR For Period Ended: December 31, 2023 ☐ Transition Report on Form 10-K ☐ Transition Report on Form 20-F ☐ Transition Report on Form 11-K ☐ Transition Report on Form 10-Q For the T |
|
| April 2, 2024 |
EX-24.1 Exhibit 24.1 VACCINEX, INC. POWER OF ATTORNEY Each of the undersigned directors and officers of Vaccinex, Inc., a Delaware corporation (the “Registrant”), hereby constitutes and appoints Maurice Zauderer, Ph.D., and Jill Sanchez, and each of them, with full power of substitution and resubstitution and full power to act without the other, his or her true and lawful attorney-in-fact and agen |
|
| April 1, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, NEITHER MAY BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| April 1, 2024 |
Exhibit 10.2 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 27, 2024, between Vaccinex, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set fort |
|
| April 1, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, NEITHER MAY BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| April 1, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| April 1, 2024 |
Exhibit 4.3 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, NEITHER MAY BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| April 1, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 27, 2024, between Vaccinex, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set fort |
|
| April 1, 2024 |
Exhibit 10.4 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of March 29, 2024, by and between Vaccinex, Inc., a Delaware corporation (the “Company”), and Alzheimer’s Drug Discovery Foundation, a Delaware non-profit corporation (the “Investor”). RECITALS WHEREAS, pursuant to that certain Securities Purchase Agreement, dated as of Marc |
|
| April 1, 2024 |
Exhibit 3.1 CERTIFICATE OF DESIGNATION OF SERIES A PREFERRED STOCK OF VACCINEX, INC. Pursuant to Section 151 of the General Corporation Law of the State of Delaware Pursuant to Section 151 of the General Corporation Law of the State of Delaware (the “DGCL”), Vaccinex, Inc., a corporation duly organized and validly existing under the laws of the State of Delaware (the “Corporation”), in accordance |
|
| April 1, 2024 |
Exhibit 10.3 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of March 29, 2024, between Vaccinex, Inc., a Delaware corporation (the “Company”), and Alzheimer’s Drug Discovery Foundation, a Delaware non-profit corporation (the “Purchaser”). WHEREAS, subject to the terms and conditions set forth in this Agreement and pursuant to Section 4(a)(2) of the |
|
| March 28, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 28, 2024 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 28, 2024 |
193,000 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-271074 Prospectus Supplement to Prospectus dated April 12, 2023 193,000 Shares of Common Stock We are offering 193,000 shares of our common stock, par value $0.0001 per share, directly to certain investors, referred to as “the investors.” In a concurrent private placement to the same investors, we are also issuing unregistered |
|
| March 27, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 27, 2024 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 4, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 27, 2024 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 21, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 21, 2024 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 21, 2024 |
Exhibit 99.1 Vaccinex Announces Multiple New Agreements for Access to ActivMAb® Antigen Virus Technology Eight new antibody discovery agreements incorporate Vaccinex’s powerful ActivMAb® Drug Discovery Platform ActivMab® platform enables the discovery and development of high value antibodies against challenging multi-pass membrane targets ROCHESTER, N.Y., February 21, 2024 –Vaccinex, Inc. (Nasdaq: |
|
| February 15, 2024 |
Vaccinex, Inc. Announces Reverse Stock Split Exhibit 99.1 Vaccinex, Inc. Announces Reverse Stock Split ROCHESTER, N.Y., February 15, 2024 (GLOBE NEWSWIRE) – Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that it will effect a 1-for-14 reverse stock split of its issued common stock, ef |
|
| February 15, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 14, 2024 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File N |
|
| February 15, 2024 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VACCINEX, INC. VACCINEX, INC., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “General Corporation Law”), hereby certifies as follows: FIRST: The name of the corporation is Vaccinex, Inc. (the “Corporation”). SECOND: The Amended and |
|
| February 13, 2024 |
US9186402023 / Vaccinex, Inc. / Fcmi Parent Co. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 9) Under the Securities Exchange Act of 1934 VACCINEX, INC. (Name of Issuer) Common Stock, Par Value $0.0001 per share (Title of Class of Securities) 918640 202 (CUSIP Number) Thomas J. Rice Baker & McKenzie LLP 452 Fifth Avenue New York NY 10018 (212) 626-4100 (Name, Address and Telephone |
|
| February 13, 2024 |
EX-99.23 Exhibit 99.23 LOCK-UP AGREEMENT February 7, 2024 Re: Securities Purchase Agreement, dated as of February 6, 2024 (the “Purchase Agreement”), between Vaccinex, Inc. (the “Company”) and the purchasers signatory thereto Ladies and Gentlemen: Defined terms not otherwise defined in this letter agreement (the “Letter Agreement”) shall have the meanings set forth in the Purchase Agreement. The u |
|
| February 13, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 8, 2024 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 12, 2024 |
US9186402023 / Vaccinex, Inc. / Zauderer Maurice - SC 13D/A Activist Investment SC 13D/A 1 d749313dsc13da.htm SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 4) Under the Securities Exchange Act of 1934 VACCINEX, INC. (Name of Issuer) Common Stock, Par Value $0.0001 per share (Title of Class of Securities) 918640 202 (CUSIP Number) Maurice Zauderer c/o Vaccinex, Inc. 1895 Mount Hope Ave Rochester, New York 14620 Tel |
|
| February 12, 2024 |
EX-99.11 2 d749313dex9911.htm EX-99.11 Exhibit 99.11 LOCK-UP AGREEMENT February 7, 2024 Re: Securities Purchase Agreement, dated as of February 6, 2024 (the “Purchase Agreement”), between Vaccinex, Inc. (the “Company”) and the purchasers signatory thereto Ladies and Gentlemen: Defined terms not otherwise defined in this letter agreement (the “Letter Agreement”) shall have the meanings set forth in |
|
| February 9, 2024 |
US9186402023 / Vaccinex, Inc. / Point72 Asset Management, L.P. - VACCINEX, INC. Passive Investment SC 13G 1 p24-0815sc13g.htm VACCINEX, INC. SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 (Amendment No. )* Vaccinex, Inc. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 918640202 (CUSIP Number) February 6, 2024 (Date of Event Which Requires Filing of this Statement) Check the appropriate bo |
|
| February 9, 2024 |
JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) EX-99 2 exhibit99.htm JOINT FILING AGREEMENT PURSUANT TO RULE 13D-1(K) EXHIBIT 99.1 JOINT FILING AGREEMENT PURSUANT TO RULE 13d-1(k) The undersigned acknowledge and agree that the foregoing statement on Schedule 13G is filed on behalf of each of the undersigned and that all subsequent amendments to this statement on Schedule 13G shall be filed on behalf of each of the undersigned without the neces |
|
| February 8, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K/A CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2024 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File |
|
| February 8, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, NEITHER MAY BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| February 7, 2024 |
Exhibit 4.2 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, NEITHER MAY BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| February 7, 2024 |
Exhibit 4.1 NEITHER THIS SECURITY NOR THE SECURITIES FOR WHICH THIS SECURITY IS EXERCISABLE HAVE BEEN REGISTERED WITH THE SECURITIES AND EXCHANGE COMMISSION OR THE SECURITIES COMMISSION OF ANY STATE IN RELIANCE UPON AN EXEMPTION FROM REGISTRATION UNDER THE SECURITIES ACT OF 1933, AS AMENDED (THE “SECURITIES ACT”), AND, ACCORDINGLY, NEITHER MAY BE OFFERED OR SOLD EXCEPT PURSUANT TO AN EFFECTIVE REG |
|
| February 7, 2024 |
Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of February 6, 2024, between Vaccinex, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions set fo |
|
| February 7, 2024 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT This Registration Rights Agreement (this “Agreement”) is made and entered into as of February 7, 2024, by and among Vaccinex, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A (each an “Investor” and collectively the “Investors”). RECITALS WHEREAS, pursuant to that certain Securities Purchase Agreement, dated as of Fe |
|
| February 7, 2024 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): February 6, 2024 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| February 7, 2024 |
US9186402023 / Vaccinex, Inc. / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G/A Amendment No. 1 Under the Securities Exchange Act of 1934 Vaccinex, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 918640202 (CUSIP Number) December 31, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pur |
|
| January 19, 2024 |
712,484 Shares of Common Stock Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-276465 PROSPECTUS 712,484 Shares of Common Stock This prospectus relates to the resale, from time to time, by the selling stockholders identified in this prospectus under the caption “Selling Stockholders,” or the Selling Stockholders, of up to 712,484 shares of our common stock, par value $0.0001 per share, comprising (i) 390 |
|
| January 17, 2024 |
Vaccinex, Inc. 1895 Mount Hope Avenue Rochester, New York 14620 Vaccinex, Inc. 1895 Mount Hope Avenue Rochester, New York 14620 January 17, 2024 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Vaccinex, Inc. Registration Statement on Form S-3 Filed January 10, 2024 File No. 333-276465 Request for Acceleration of Effectiveness Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Sec |
|
| January 10, 2024 |
Exhibit 24.1 VACCINEX, INC. POWER OF ATTORNEY Each of the undersigned directors and officers of Vaccinex, Inc., a Delaware corporation (the “Registrant”), hereby constitutes and appoints Maurice Zauderer, Ph.D., and Scott E. Royer, CFA, MBA, and each of them, with full power of substitution and resubstitution and full power to act without the other, his or her true and lawful attorney-in-fact and |
|
| January 10, 2024 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Vaccinex, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit (2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, |
|
| January 10, 2024 |
As filed with the Securities and Exchange Commission on January 10, 2024 S-3 Table of Contents As filed with the Securities and Exchange Commission on January 10, 2024 Registration Statement No. |
|
| January 8, 2024 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| December 28, 2023 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| November 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38624 Vaccinex, Inc. ( |
|
| October 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 26, 2023 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| October 26, 2023 |
EX-99.1 Exhibit 99.1 Vaccinex Reports Positive Effect of Pepinemab Treatment on New Biomarker of Brain Inflammation in Neurodegenerative Diseases Pepinemab, anti-SEMA4D blocking antibody, appears to inhibit astrocyte activation and brain inflammation as evidenced by significantly reduced levels of GFAP in patient blood. ROCHESTER, N.Y., October 26, 2023 — Vaccinex, Inc. (Nasdaq: VCNX), a clinical- |
|
| October 18, 2023 |
EX-99.19 2 d459504dex9919.htm EX-99.19 Exhibit 99.19 COMMON STOCK PURCHASE WARRANT VACCINEX, INC. Warrant Shares: 3,000,000 Initial Exercise Date: October 3, 2023 Issue Date: October 3, 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, FCMI Parent Co. or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and t |
|
| October 18, 2023 |
VCNX / Vaccinex Inc / Fcmi Parent Co. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 8) Under the Securities Exchange Act of 1934 VACCINEX, INC. (Name of Issuer) Common Stock, Par Value $0.0001 per share (Title of Class of Securities) 918640 202 (CUSIP Number) Thomas J. Rice Baker & McKenzie LLP 452 Fifth Avenue New York NY 10018 (212) 626-4100 (Name, Address and Telephone |
|
| October 18, 2023 |
EX-99.20 3 d459504dex9920.htm EX-99.20 Exhibit 99.20 LOCK-UP AGREEMENT September 28, 2023 Re: Securities Purchase Agreement, dated as of September 28, 2023 (the “Purchase Agreement”), between Vaccinex, Inc. (the “Company”) and the purchasers signatory thereto Ladies and Gentlemen: Defined terms not otherwise defined in this letter agreement (the “Letter Agreement”) shall have the meanings set fort |
|
| October 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2023 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| October 12, 2023 |
VCNX / Vaccinex Inc / Zauderer Maurice - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 3) Under the Securities Exchange Act of 1934 VACCINEX, INC. (Name of Issuer) Common Stock, Par Value $0.0001 per share (Title of Class of Securities) 918640 202 (CUSIP Number) Maurice Zauderer c/o Vaccinex, Inc. 1895 Mount Hope Ave Rochester, New York 14620 Telephone: (585) 271-2700 (Name, |
|
| October 12, 2023 |
EX-99.8 Exhibit 99.8 LOCK-UP AGREEMENT September , 2023 Re: Securities Purchase Agreement, dated as of September [ ], 2023 (the “Purchase Agreement”), between Vaccinex, Inc. (the “Company”) and the purchasers signatory thereto Ladies and Gentlemen: Defined terms not otherwise defined in this letter agreement (the “Letter Agreement”) shall have the meanings set forth in the Purchase Agreement. The |
|
| October 11, 2023 |
VCNX / Vaccinex Inc / HIRSCHMAN ORIN Passive Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13G Under the Securities Exchange Act of 1934 Vaccinex, Inc. (Name of Issuer) Common Stock, $0.0001 par value per share (Title of Class of Securities) 918640202 (CUSIP Number) September 28, 2023 (Date of Event Which Requires Filing of this Statement) Check the appropriate box to designate the rule pursuant to which th |
|
| October 4, 2023 |
EX-10.1 Exhibit 10.1 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September 28, 2023, between Vaccinex, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditi |
|
| October 4, 2023 |
Exhibit 1.1 September 28, 2023 Vaccinex, Inc. Attention: Mr. Maurice Zauderer, Ph.D. 1895 Mount Hope Avenue Rochester, New York 14620 Dear Dr. Zauderer: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent” or “A.G.P.”) and Vaccinex, Inc., a Delaware corporation (the “Company”), that the Placement Agent shall serve as the exclusive p |
|
| October 4, 2023 |
EX-4.2 Exhibit 4.2 FORM OF COMMON STOCK PURCHASE WARRANT VACCINEX, INC. Warrant Shares: Initial Exercise Date: October 3, 2023 Issue Date: October 3, 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on |
|
| October 4, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 28, 2023 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File |
|
| October 4, 2023 |
Exhibit 4.1 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT VACCINEX, INC. Warrant Shares: Initial Exercise Date: October 3, 2023 Issue Date: October 3, 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, |
|
| October 2, 2023 |
Table of Contents Filed pursuant to Rule 424(b)(4) Registration No. 333-274520 PROSPECTUS 7,600,000 Shares of Common Stock Pre-Funded Warrants to Purchase up to 2,000,000 Shares of Common Stock Common Warrants to Purchase up to 9,600,000 Shares of Common Stock 2,000,000 Shares of Common Stock Underlying such Pre-Funded Warrants 9,600,000 Shares of Common Stock Underlying such Common Warrants We ar |
|
| September 28, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Vaccinex, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Carry |
|
| September 28, 2023 |
As filed with the Securities and Exchange Commission on September 28, 2023 As filed with the Securities and Exchange Commission on September 28, 2023 Registration Statement No. |
|
| September 27, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 27, 2023 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File |
|
| September 26, 2023 |
Form of Securities Purchase Agreement. Exhibit 10.18 SECURITIES PURCHASE AGREEMENT This Securities Purchase Agreement (this “Agreement”) is dated as of September [●], 2023, between Vaccinex, Inc., a Delaware corporation (the “Company”), and each purchaser identified on the signature pages hereto (each, including its successors and assigns, a “Purchaser” and collectively the “Purchasers”). WHEREAS, subject to the terms and conditions se |
|
| September 26, 2023 |
Exhibit 99.1 Vaccinex Reports Groundbreaking Findings at Medical Conferences Supporting Development of Pepinemab for the Treatment of Neurodegenerative Diseases and Cancer “Pepinemab, a SEMA4D blocking antibody, is a novel potential treatment for neurodegenerative disease” will be a podium presentation at the 16th edition of the Clinical Trials on Alzheimer’s Disease Conference to be held in Bosto |
|
| September 26, 2023 |
Form of Placement Agent Agreement. Exhibit 1.1 September [ ], 2023 Vaccinex, Inc. Attention: Mr. Maurice Zauderer, Ph.D. 1895 Mount Hope Avenue Rochester, New York 14620 Dear Dr. Zauderer: This letter (the “Agreement”) constitutes the agreement between A.G.P./Alliance Global Partners (the “Placement Agent” or “A.G.P.”) and Vaccinex, Inc., a Delaware corporation (the “Company”), that the Placement Agent shall serve as the exclusive |
|
| September 26, 2023 |
As filed with the Securities and Exchange Commission on September 26, 2023 Table of Contents As filed with the Securities and Exchange Commission on September 26, 2023 Registration Statement No. |
|
| September 26, 2023 |
Form of Common Stock Purchase Warrant. Exhibit 4.4 FORM OF COMMON STOCK PURCHASE WARRANT VACCINEX, INC. Warrant Shares: Initial Exercise Date: [ ], 2023 Issue Date: [ ], 2023 THIS COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any time on or after [ ], 2023 |
|
| September 26, 2023 |
VCNX / Vaccinex Inc / Zauderer Maurice - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 2) Under the Securities Exchange Act of 1934 VACCINEX, INC. (Name of Issuer) Common Stock, Par Value $0.0001 per share (Title of Class of Securities) 918640 202 (CUSIP Number) Maurice Zauderer c/o Vaccinex, Inc. 1895 Mount Hope Ave Rochester, New York 14620 Telephone: (585) 271-2700 (Name, |
|
| September 26, 2023 |
Exhibit 4.3 FORM OF PRE-FUNDED COMMON STOCK PURCHASE WARRANT VACCINEX, INC. Warrant Shares: Initial Exercise Date: [ ], 2023 Issue Date: [ ], 2023 THIS PRE-FUNDED COMMON STOCK PURCHASE WARRANT (the “Warrant”) certifies that, for value received, or its assigns (the “Holder”) is entitled, upon the terms and subject to the limitations on exercise and the conditions hereinafter set forth, at any |
|
| September 26, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 26, 2023 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File |
|
| September 26, 2023 |
Vaccinex, Inc. 1895 Mount Hope Avenue Rochester, New York 14620 Vaccinex, Inc. 1895 Mount Hope Avenue Rochester, New York 14620 September 26, 2023 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Vaccinex, Inc. Registration Statement on Form S-1 File No. 333-274520 Request for Acceleration of Effectiveness Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securities Act |
|
| September 26, 2023 |
September 26, 2023 VIA EDGAR U.S. Securities and Exchange Commission Division of Corporation Finance 100 F Street, N.E. Washington, D.C. 20549 Re: Vaccinex, Inc. Registration Statement on Form S-1 File No. 333-274520 Ladies and Gentlemen: In accordance with Rule 461 of the General Rules and Regulations promulgated under the Securities Act of 1933, as amended (the “Act”), A.G.P./ALLIANCE GLOBAL |
|
| September 22, 2023 |
Vaccinex, Inc. Announces Reverse Stock Split Exhibit 99.1 Vaccinex, Inc. Announces Reverse Stock Split ROCHESTER, N.Y., September 22, 2023 – Vaccinex, Inc., (NASDAQ: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating neurodegenerative disease and cancer through the inhibition of SEMA4D, today announced that it will effect a 1-for-15 reverse stock split of its issued common stock, effective at 5:00 |
|
| September 22, 2023 |
Exhibit 3.1 CERTIFICATE OF AMENDMENT OF THE AMENDED AND RESTATED CERTIFICATE OF INCORPORATION OF VACCINEX, INC. VACCINEX, INC., a corporation organized and existing under and by virtue of the General Corporation Law of the State of Delaware (the “General Corporation Law”), hereby certifies as follows: FIRST: The name of the corporation is Vaccinex, Inc. (the “Corporation”). SECOND: The Amended and |
|
| September 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 22, 2023 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File |
|
| September 22, 2023 |
Entry into a Material Definitive Agreement, Unregistered Sales of Equity Securities UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 20, 2023 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commissio |
|
| September 22, 2023 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of September 20, 2023, by and among Vaccinex, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A (each an “Investor” and collectively the “Investors”). RECITALS WHEREAS, pursuant to that certain Stock Purchase Agreement, dated as of Septe |
|
| September 22, 2023 |
Exhibit 10.1 STOCK PURCHASE AGREEMENT Table of Contents Page Section 1. Purchase and Sale of Common Stock 1 1.1 Sale and Issuance of the Shares 1 1.2 Closing; Delivery 1 1.3 Defined Terms Used in this Agreement 2 1.4 Construction 3 Section 2. Representations and Warranties of the Company 4 2.1 Organization, Good Standing and Qualification 4 2.2 Authorization 4 2.3 Capitalization 4 2.4 Valid Issuan |
|
| September 14, 2023 |
Exhibit 107 Calculation of Filing Fee Tables Form S-1 (Form Type) Vaccinex, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered and Carry Forward Securities Security Type Security Class Title Fee Calculation or Carry Forward Rule Amount Registered Proposed Maximum Offering Price Per Unit Maximum Aggregate Offering Price(1) Fee Rate Amount of Registration Fee Carry |
|
| September 14, 2023 |
Exhibit 24.1 VACCINEX, INC. POWER OF ATTORNEY Each of the undersigned directors and officers of Vaccinex, Inc., a Delaware corporation (the “Registrant”), hereby constitutes and appoints Maurice Zauderer, Ph.D. and Scott E. Royer, CFA, MBA, and each of them, with full power of substitution and resubstitution and full power to act without the other, his or her true and lawful attorney-in-fact and a |
|
| September 14, 2023 |
As filed with the Securities and Exchange Commission on September 14, 2023 S-1 Table of Contents As filed with the Securities and Exchange Commission on September 14, 2023 Registration Statement No. |
|
| September 13, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 8, 2023 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File N |
|
| August 22, 2023 |
Stock Purchase Agreement by and between the Company and the Investors, dated as of August 18, 2023 EX-10.1 Exhibit 10.1 STOCK PURCHASE AGREEMENT Table of Contents Page Section 1. Purchase and Sale of Common Stock 1 1.1 Sale and Issuance of the Shares 1 1.2 Closing; Delivery 1 1.3 Defined Terms Used in this Agreement 2 1.4 Construction 3 Section 2. Representations and Warranties of the Company 4 2.1 Organization, Good Standing and Qualification 4 2.2 Authorization 4 2.3 Capitalization 4 2.4 Vali |
|
| August 22, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 18, 2023 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Num |
|
| August 22, 2023 |
EX-10.2 Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of August 18, 2023, by and among Vaccinex, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A (each an “Investor” and collectively the “Investors”). RECITALS WHEREAS, pursuant to that certain Stock Purchase Agreement, dated as of |
|
| August 14, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38624 Vaccinex, Inc. (Exact |
|
| August 14, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| August 4, 2023 |
PRE 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| July 11, 2023 |
3,815,642 Shares of Common Stock 424B3 Table of Contents Filed pursuant to Rule 424(b)(3) Registration No. 333-272649 PROSPECTUS 3,815,642 Shares of Common Stock This prospectus relates to the resale, from time to time, by the selling stockholders identified in this prospectus under the caption “Selling Stockholders,” or the Selling Stockholders, of up to 3,815,642 shares of our common stock, par value $0.0001 per share. We are n |
|
| July 7, 2023 |
Vaccinex, Inc. 1895 Mount Hope Avenue Rochester, New York 14620 CORRESP Vaccinex, Inc. 1895 Mount Hope Avenue Rochester, New York 14620 July 7, 2023 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Vaccinex, Inc. Registration Statement on Form S-3 Filed June 14, 2023 File No. 333-272649 Request for Acceleration of Effectiveness Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Se |
|
| June 14, 2023 |
Registration Rights Agreement, by and among the Company and certain Investors, dated March 30, 2023. EX-4.2 Exhibit 4.2 Execution Version REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of March 30, 2023, by and between Vaccinex, Inc., a Delaware corporation (the “Company”), and Lublin Financial Corporation (the “Investor”). RECITALS WHEREAS, pursuant to that certain Stock Purchase Agreement, dated as of March 30, 2023, by and betwee |
|
| June 14, 2023 |
EX-24.1 Exhibit 24.1 VACCINEX, INC. POWER OF ATTORNEY Each of the undersigned directors and officers of Vaccinex, Inc., a Delaware corporation (the “Registrant”), hereby constitutes and appoints Maurice Zauderer, Ph.D. and Scott E. Royer, CFA, MBA, and each of them, with full power of substitution and resubstitution and full power to act without the other, his or her true and lawful attorney-in-fa |
|
| June 14, 2023 |
U.S. Securities and Exchange Commission Youâve Exceeded the SECâs Traffic Limit Your request rate has exceeded the SECâs maximum allowable requests per second. Your access to SEC.gov will be limited for 10 minutes. Current guidelines limit each user to a total of no more than 10 requests per second, regardless of the number of machines used to submit requests. To ensure that SEC.gov remains |
|
| June 14, 2023 |
As filed with the Securities and Exchange Commission on June 14, 2023 S-3 1 d497735ds3.htm S-3 Table of Contents As filed with the Securities and Exchange Commission on June 14, 2023 Registration Statement No. 333- UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM S-3 REGISTRATION STATEMENT UNDER THE SECURITIES ACT OF 1933 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware (State or other jurisdiction of incorpo |
|
| June 14, 2023 |
Registration Rights Agreement, by and among the Company and certain Investors, dated May 15, 2023. EX-4.3 Exhibit 4.3 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of May 15, 2023, by and among Vaccinex, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A (each an “Investor” and collectively the “Investors”). RECITALS WHEREAS, pursuant to that certain Stock Purchase Agreement, dated as of May 1 |
|
| June 14, 2023 |
EX-4.4 Exhibit 4.4 Execution Version REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of May 17, 2023, by and between Vaccinex, Inc., a Delaware corporation (the “Company”), and Alzheimer’s Drug Discovery Foundation, a Delaware non-profit corporation (the “Investor”). RECITALS WHEREAS, pursuant to that certain Stock Purchase Agreement, |
|
| May 30, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 25, 2023 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 25, 2023 |
VCNX / Vaccinex Inc / Fcmi Parent Co. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 7) Under the Securities Exchange Act of 1934 VACCINEX, INC. (Name of Issuer) Common Stock, Par Value $0.0001 per share (Title of Class of Securities) 918640 103 (CUSIP Number) Thomas J. Rice Baker & McKenzie LLP 452 Fifth Avenue New York NY 10018 (212) 626-4100 (Name, Address and Telephone |
|
| May 19, 2023 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 19, 2023 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 19, 2023 |
Table of Contents Filed Pursuant to Rule 424(b)(5) Registration No. 333-271074 PROSPECTUS SUPPLEMENT (To Prospectus dated April 12, 2023) Up to $4,391,000 Common Stock We previously entered into an Open Market Sale AgreementSM, or sales agreement, with Jefferies LLC, or Jefferies, dated March 27, 2020, relating to shares of our common stock, par value $0.0001 per share, offered by this prospectus |
|
| May 15, 2023 |
EX-10.1 Exhibit 10.1 STOCK PURCHASE AGREEMENT Table of Contents Page Section 1. Purchase and Sale of Common Stock 1 1.1 Sale and Issuance of the Shares 1 1.2 Closing; Delivery 1 1.3 Defined Terms Used in this Agreement 2 1.4 Construction 3 Section 2. Representations and Warranties of the Company 4 2.1 Organization, Good Standing and Qualification 4 2.2 Authorization 4 2.3 Capitalization 4 2.4 Vali |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38624 Vaccinex, Inc. (Exac |
|
| May 15, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2023 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Number |
|
| May 12, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 11, 2023 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 10, 2023 |
Vaccinex, Inc. 1895 Mount Hope Avenue Rochester, New York 14620 CORRESP Vaccinex, Inc. 1895 Mount Hope Avenue Rochester, New York 14620 April 10, 2023 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Vaccinex, Inc. Registration Statement on Form S-3 Filed April 3, 2023 File No. 333-271074 Request for Acceleration of Effectiveness Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the |
|
| April 6, 2023 |
DEF 14A Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D. |
|
| April 5, 2023 |
VCNX / Vaccinex Inc / Fcmi Parent Co. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 6) Under the Securities Exchange Act of 1934 VACCINEX, INC. (Name of Issuer) Common Stock, Par Value $0.0001 per share (Title of Class of Securities) 918640 103 (CUSIP Number) Thomas J. Rice Baker & McKenzie LLP 452 Fifth Avenue New York NY 10018 (212) 626-4100 (Name, Address and Telephone |
|
| April 3, 2023 |
EX-24.1 Exhibit 24.1 VACCINEX, INC. POWER OF ATTORNEY Each of the undersigned directors and officers of Vaccinex, Inc., a Delaware corporation (the “Registrant”), hereby constitutes and appoints Maurice Zauderer, Ph.D. and Scott E. Royer, CFA, MBA, and each of them, with full power of substitution and resubstitution and full power to act without the other, his or her true and lawful attorney-in-fa |
|
| April 3, 2023 |
As filed with the Securities and Exchange Commission on April 3, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on April 3, 2023 Registration Statement No. |
|
| April 3, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Tables S-3 (Form Type) Vaccinex, Inc. |
|
| April 3, 2023 |
Exhibit 4.4 INDENTURE DATED AS OF , 20 BETWEEN VACCINEX, INC. as Issuer, AND as Trustee Providing for Issuance of Senior Debt Securities in Series TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions 1 Section 1.02 Compliance Certificates and Opinions 6 Section 1.03 Form of Documents Delivered to Trustee 6 Section 1.04 Acts of Holders |
|
| April 3, 2023 |
Form of Subordinated Debt Indenture EX-4.6 Exhibit 4.6 INDENTURE DATED AS OF , 20 BETWEEN VACCINEX, INC. as Issuer, AND as Trustee Providing for Issuance of Subordinated Debt Securities in Series TABLE OF CONTENTS Page ARTICLE I. DEFINITIONS AND OTHER PROVISIONS OF GENERAL APPLICATION 1 Section 1.01 Definitions 1 Section 1.02 Compliance Certificates and Opinions 6 Section 1.03 Form of Documents Delivered to Trustee 6 Section 1.04 Ac |
|
| April 3, 2023 |
Exhibit 10.1 Execution Version STOCK PURCHASE AGREEMENT Table of Contents Page Section 1. Purchase and Sale of Common Stock 1 1.1 Sale and Issuance of the Shares 1 1.2 Closing; Delivery 1 1.3 Defined Terms Used in this Agreement 2 1.4 Construction 4 Section 2. Representations and Warranties of the Company 4 2.1 Organization, Good Standing and Qualification 4 2.2 Authorization 4 2.3 Capitalization |
|
| April 3, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2023 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 31, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38624 Vaccinex, Inc. |
|
| March 23, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 17, 2023 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 9, 2023 |
EX-99.1 Exhibit 99.1 Vaccinex Reports that KEYNOTE B-84 has Reached Targeted Enrollment for Pre-planned Interim Analysis Interim analysis will be performed when the last of these patients has completed a tumor assessment scan approximately 9 weeks after initiating treatment The open-label Phase 1b/2 KEYNOTE B-84 study is evaluating the use of pepinemab in combination with Merck’s KEYTRUDA® (pembro |
|
| March 9, 2023 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 9, 2023 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| February 1, 2023 |
1,616,331 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-269385 PROSPECTUS 1,616,331 Shares of Common Stock This prospectus relates to the resale, from time to time, by the selling stockholders identified in this prospectus under the caption “Selling Stockholders,” or the Selling Stockholders, of up to 1,616,331 shares of our common stock, par value $0.0001 per share. We are not sel |
|
| January 27, 2023 |
Vaccinex, Inc. 1895 Mount Hope Avenue Rochester, New York 14620 CORRESP 1 filename1.htm Vaccinex, Inc. 1895 Mount Hope Avenue Rochester, New York 14620 January 27, 2023 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Vaccinex, Inc. Registration Statement on Form S-3 Filed January 24, 2023 File No. 333-269385 Request for Acceleration of Effectiveness Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and R |
|
| January 24, 2023 |
EX-24.1 Exhibit 24.1 VACCINEX, INC. POWER OF ATTORNEY Each of the undersigned directors and officers of Vaccinex, Inc., a Delaware corporation (the “Registrant”), hereby constitutes and appoints Maurice Zauderer, Ph.D. and Scott E. Royer, CFA, MBA, and each of them, with full power of substitution and resubstitution and full power to act without the other, his or her true and lawful attorney-in-fa |
|
| January 24, 2023 |
EX-FILING FEES Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Vaccinex, Inc. |
|
| January 24, 2023 |
As filed with the Securities and Exchange Commission on January 24, 2023 S-3 Table of Contents As filed with the Securities and Exchange Commission on January 24, 2023 Registration Statement No. |
|
| November 29, 2022 |
VCNX / Vaccinex Inc / Fcmi Parent Co. - SC 13D/A Activist Investment SC 13D/A UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 5) Under the Securities Exchange Act of 1934 VACCINEX, INC. (Name of Issuer) Common Stock, Par Value $0.0001 per share (Title of Class of Securities) 918640 103 (CUSIP Number) Thomas J. Rice Baker & McKenzie LLP 452 Fifth Avenue New York NY 10018 (212) 626-4100 (Name, Address and Telephone |
|
| November 28, 2022 |
VCNX / Vaccinex Inc / Zauderer Maurice - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 1) Under the Securities Exchange Act of 1934 VACCINEX, INC. (Name of Issuer) Common Stock, Par Value $0.0001 per share (Title of Class of Securities) 918640 103 (CUSIP Number) Maurice Zauderer c/o Vaccinex, Inc. 1895 Mount Hope Ave Rochester, New York 14620 Telephone: (585) 271-2700 (Name, Address a |
|
| November 25, 2022 |
EX-10.2 Exhibit 10.2 Execution Version REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this “Agreement”) is made and entered into as of November 22, 2022, by and between Vaccinex, Inc., a Delaware corporation (the “Company”), and the Investors identified on Exhibit A (each an “Investor” and collectively the “Investors”). RECITALS WHEREAS, pursuant to that certain Stock Purchase A |
|
| November 25, 2022 |
EX-10.1 Exhibit 10.1 Execution Version STOCK PURCHASE AGREEMENT Table of Contents Page Section 1. Purchase and Sale of Common Stock 1 1.1 Sale and Issuance of the Shares 1 1.2 Closing; Delivery 2 1.3 Defined Terms Used in this Agreement 2 1.4 Construction 4 Section 2. Representations and Warranties of the Company 4 2.1 Organization, Good Standing and Qualification 4 2.2 Authorization 4 2.3 Capital |
|
| November 25, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 18, 2022 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File N |
|
| November 14, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38624 Vaccinex, Inc. ( |
|
| November 10, 2022 |
EX-99.1 Exhibit 99.1 Vaccinex and its Collaborators Present Two Abstracts Related to Pepinemab Combination Immunotherapy Trials at 37th Annual Meeting of Society for Immunotherapy of Cancer New Biomarkers of Response and Resistance that Suggest Pepinemab Could Offer New Combination Treatment Options ROCHESTER, N.Y., November 10, 2022 — Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology |
|
| November 10, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): November 10, 2022 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File N |
|
| October 11, 2022 |
Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 10, 2022 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| September 13, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): September 12, 2022 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File |
|
| September 13, 2022 |
Exhibit 99.1 Neoadjuvant Pepinemab in Combination with Nivolumab and/or Ipilimumab in Resectable Stage III Melanoma NCT03769155 Michael Lowe, MD, MA, FACS, FSSO Associate Professor of Surgery Emory University School of Medicine Atlanta, GA, USA 09.12.2022 DECLARATION OF INTERESTS Michael Lowe Research Funding: Amgen,BMS, Delcath, Merck, Regeneron, Stryker,Vaccinex Advisory Board: BMS Content of th |
|
| August 15, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38624 Vaccinex, Inc. (Exact |
|
| August 8, 2022 |
EX-99.1 Exhibit 99.1 Vaccinex, Inc.’s Phase 2 “SIGNAL” Study to Evaluate Pepinemab Antibody in Huntington’s Disease is Published in Nature Medicine along with Detailed Mechanism of Action Study in Journal of Neuroinflammation Data suggest that pepinemab slows or prevents cognitive decline in Huntington’s Disease (HD) Results highlight the potential for impact on other neurodegenerative and neuroin |
|
| August 8, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): August 6, 2022 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| August 1, 2022 |
Exhibit 99.1 Vaccinex, Inc. Announces Presentation at the 2022 Alzheimer?s Association International Conference Updating the SIGNAL-AD Study of Pepinemab in Patients with Alzheimer?s Disease ROCHESTER, N.Y., July 29, 2022 ? Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering a differentiated approach to treating cancer and neurodegenerative disease through the inhibiti |
|
| August 1, 2022 |
Terrence Fisher1, E. Evans1, M. Boise1, A. Foster1, V. Mishra1, C. Mallow1, E. Smith1, J. Leonard1, A. Feigin2, E. Siemers3, K. Walters4, E. Sheldon5, R. Turner6, M. Farlow7, A. Porsteinsson8, W. Bond9 , M. Zauderer1. 1 Vaccinex, Inc.; 2 for the Huntington Study Group, and SIGNAL-HD investigators and coordinators; 3 Siemers Integration LLC; 4 for Statistics Collaborative; 5 for JEM Research; 6 for |
|
| August 1, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): July 29, 2022 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| June 10, 2022 |
KEYNOTE-B84 Study in HNSCC June 10, 2022 Pepinemab ? Anti-SEMA4D Antibody for Cancer Immunotherapy Exhibit 99. |
|
| June 10, 2022 |
Regulation FD Disclosure, Financial Statements and Exhibits UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): June 10, 2022 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| May 17, 2022 |
Up to $11,350,000 Common Stock Filed Pursuant to Rule 424(b)(5) Registration No. 333-236416 PROSPECTUS SUPPLEMENT (To Prospectus Supplement dated September 9, 2020 To Prospectus dated March 11, 2020) Up to $11,350,000 Common Stock This prospectus supplement amends and supplements the information in the prospectus, dated March 11, 2020, filed with the Securities and Exchange Commission as a part of our registration statement on |
|
| May 16, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2022 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38624 Vaccinex, Inc. (Exac |
|
| May 13, 2022 |
Submission of Matters to a Vote of Security Holders UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): May 12, 2022 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Number |
|
| April 29, 2022 |
3,252,251 Shares of Common Stock Table of Contents Filed Pursuant to Rule 424(b)(3) Registration No. 333-264236 PROSPECTUS 3,252,251 Shares of Common Stock This prospectus relates to the resale, from time to time, by the selling stockholders identified in this prospectus under the caption ?Selling Stockholders,? or the Selling Stockholders, of up to 3,252,251 shares of our common stock, par value $0.0001 per share. We are not sel |
|
| April 25, 2022 |
Vaccinex, Inc. 1895 Mount Hope Avenue Rochester, New York 14620 Vaccinex, Inc. 1895 Mount Hope Avenue Rochester, New York 14620 April 25, 2022 VIA EDGAR Securities and Exchange Commission 100 F Street, N.E. Washington, D.C. 20549 Re: Vaccinex, Inc. Registration Statement on Form S-3 Filed April 11, 2022 File No. 333-264236 Request for Acceleration of Effectiveness Ladies and Gentlemen: Pursuant to Rule 461 of the General Rules and Regulations under the Securit |
|
| April 11, 2022 |
Exhibit 24.1 VACCINEX, INC. POWER OF ATTORNEY Each of the undersigned directors and officers of Vaccinex, Inc., a Delaware corporation (the ?Registrant?), hereby constitutes and appoints Maurice Zauderer, Ph.D. and Scott E. Royer, CFA, MBA, and each of them, with full power of substitution and resubstitution and full power to act without the other, his or her true and lawful attorney-in-fact and a |
|
| April 11, 2022 |
As filed with the Securities and Exchange Commission on April 11, 2022 Table of Contents As filed with the Securities and Exchange Commission on April 11, 2022 Registration Statement No. |
|
| April 11, 2022 |
Exhibit 107 Calculation of Filing Fee Table Form S-3 (Form Type) Vaccinex, Inc. (Exact Name of Registrant as Specified in its Charter) Table 1: Newly Registered Securities Security Type Security Class Title Fee Calculation Rule Amount Registered(1) Proposed Maximum Offering Price Per Unit(2) Maximum Aggregate Offering Price Fee Rate Amount of Registration Fee Fees to Be Paid Equity Common Stock, p |
|
| April 5, 2022 |
Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 14A (Rule 14a-101) INFORMATION REQUIRED IN PROXY STATEMENT SCHEDULE 14A INFORMATION Proxy Statement Pursuant to Section 14(a) of the Securities Exchange Act of 1934 Filed by the Registrant ? Filed by a party other than the Registrant ? Check the appropriate box: ? Preliminary Proxy Statement ? Confid |
|
| April 4, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 30, 2022 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Numb |
|
| March 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ? ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 FOR THE TRANSITION PERIOD FROM TO Commission File Number 001-38624 Vaccinex, Inc. |
|
| March 8, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): March 3, 2022 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Numbe |
|
| February 14, 2022 |
VCNX / Vaccinex Inc / Fcmi Parent Co. - SC 13D/A Activist Investment UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D (Amendment No. 4) Under the Securities Exchange Act of 1934 VACCINEX, INC. (Name of Issuer) Common Stock, Par Value $0.0001 per share (Title of Class of Securities) 918640 103 (CUSIP Number) Thomas J. Rice Baker & McKenzie LLP 452 Fifth Avenue New York NY 10018 (212) 626-4100 (Name, Address and Telephone Number of |
|
| February 10, 2022 |
VCNX / Vaccinex Inc / Zauderer Maurice - SC 13D Activist Investment SC 13D UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 SCHEDULE 13D Under the Securities Exchange Act of 1934 (Amendment No. ) VACCINEX, INC. (Name of Issuer) Common Stock, par value $0.0001 per share (Title of Class of Securities) 918640 103 (CUSIP Number) Maurice Zauderer c/o Vaccinex, Inc. 1895 Mount Hope Ave Rochester, New York 14620 Telephone: (585) 271-2700 (Name, Add |
|
| February 10, 2022 |
JOINT FILING AGREEMENT AMONG MAURICE ZAUDERER and VACCINEX (ROCHESTER) L.L.C. Exhibit 99.1 JOINT FILING AGREEMENT AMONG MAURICE ZAUDERER and VACCINEX (ROCHESTER) L.L.C. WHEREAS, in accordance with Rule 13d-1(k) under the Securities and Exchange Act of 1934, as amended (the ?Act?), only one joint Statement and any amendments thereto need be filed whenever one or more persons are required to file such a Statement or any amendments thereto pursuant to Section 13(d) of the Act |
|
| January 31, 2022 |
Exhibit 10.2 REGISTRATION RIGHTS AGREEMENT THIS REGISTRATION RIGHTS AGREEMENT (this ?Agreement?) is made and entered into as of January 31, 2022, by and between Vaccinex, Inc., a Delaware corporation (the ?Company?), and the Investors identified on Exhibit A (each an ?Investor? and collectively the ?Investors?). RECITALS WHEREAS, pursuant to that certain Stock Purchase Agreement, dated as of Janua |
|
| January 31, 2022 |
Exhibit 99.1 Vaccinex Announces $6.6 Million Private Placement Participants include a syndicate of existing and new shareholders Contributes to total of $10.1 million in new equity financing for January, 2022 ROCHESTER, N.Y., Jan. 27, 2022 (GLOBE NEWSWIRE) ? Vaccinex, Inc. (Nasdaq: VCNX), a clinical-stage biotechnology company pioneering novel investigational antibody therapies in cancer and neuro |
|
| January 31, 2022 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 27, 2022 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| January 31, 2022 |
Exhibit 10.1 Execution Version STOCK PURCHASE AGREEMENT Table of Contents Page Section 1. Purchase and Sale of Common Stock 1 1.1 Sale and Issuance of the Shares 1 1.2 Closing; Delivery 1 1.3 Defined Terms Used in this Agreement 2 1.4 Construction 4 Section 2. Representations and Warranties of the Company 4 2.1 Organization, Good Standing and Qualification 4 2.2 Authorization 4 2.3 Capitalization |
|
| January 26, 2022 |
Exhibit 99.1 Vaccinex Reports Two Complete Responses in First Three Patients Enrolled in the Phase 1b/2 KEYNOTE-B84 Study of Pepinemab in Combination with KEYTRUDA? (pembrolizumab) in Patients with Recurrent or Metastatic Head and Neck Cancer ROCHESTER, N.Y., January 26, 2022 ? Vaccinex, Inc. (Nasdaq: VCNX, Vaccinex, the Company), a clinical-stage biotechnology company pioneering a differentiated |
|
| January 26, 2022 |
Financial Statements and Exhibits, Other Events UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 8-K CURRENT REPORT Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 26, 2022 Vaccinex, Inc. (Exact name of registrant as specified in its charter) Delaware 001-38624 16-1603202 (State or other jurisdiction of incorporation) (Commission File Nu |
|
| November 8, 2021 |
UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ? QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2021 OR ? TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-38624 Vaccinex, Inc. ( |
